KC-6731

NCI-H292-FGFR2B Cell Line

66380

Home » NCI-H292-FGFR2B Cell Line

Background of NCI-H292-FGFR2B Cell Line

FGFR2B is an epithelial-specific isoform of fibroblast growth factor receptor 2, generated by alternative splicing of the FGFR2 gene. It primarily binds to mesenchymal-derived FGF ligands (e.g., FGF7, FGF10) and plays critical roles in embryonic development, tissue repair, and epithelial homeostasis. In oncology, aberrant activation of FGFR2B—through overexpression, amplification, or ligand-dependent signaling—drives tumor progression in multiple cancers, particularly gastric, breast, and endometrial carcinomas. Its restricted expression pattern and ligand specificity make it a compelling therapeutic target, with inhibitors currently developed to block hyperactivated FGFR2B pathways in precision medicine.

Specifications

Catalog Number	KC-6731
Cell Line Name	NCI-H292-FGFR2B Cell Line
NCBI/UniProt Accession Number	NM_022970.3
Clone Number	1#
Host Cell Line	Human NCI-H292 Cell Line
Description	Stable NCI-H292 cell line expressing exogenous human FGFR2B gene
Quantity	Two vials of frozen cells (≥2-10⁶/vial)
Stability	Stable in culture over a minimum of 10 passages
Application	Drug screening and biological assays
Freezing Medium	70% basal medium+20% FBS+10% DMSO
Propagation Medium	RPMI1640+10% FBS +1μg/mL Puromycin
Selection Marker	Puromycin
Morphology	Epithelial-like
Subculture	Split saturated culture 1:3-1:4 every 2-3 days
Incubation	37 °C with 5% CO₂
Storage	Liquid nitrogen immediately upon receiving
Doubling Time	Approximately 48 hours
Mycoplasma Status	Negative

Cell Line Generation

NCI-H292-FGFR2B cell line was generated using a lentiviral vector expressing the human FGFR2B sequence.

Characterization

Cell Resuscitation

Pre-warm complete culture medium (RPMI1640+10% FBS +1μg/mL Puromycin) in a 37°C water bath.
Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
Incubate the flask in a 37°C in a humidified 5% CO₂ incubator.
Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
Subculture the cells at a ratio of 1:3-1:4 every 2-3 days upon reaching 80%–90% confluency.

Cell Freezing

Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
Pre-chill the freezing medium on ice and label the cryovials accordingly.
Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
Gently resuspend the cell pellet in chilled freezing medium, ensuring a minimum cell density of 3×10⁶ cells/mL.
Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

1. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, Wang J, Yu K, Chatterjee N, Orr N, Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Hayes RB, Tucker M, Gerhard DS, Fraumeni JF, Hoover RN, Thomas G, Chanock SJ (Jul 2007). A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nature Genetics
2. Rha SY, Zhang Y, Elme A, Pazo Cid R, Alacacioglu A, Ziogas DC, Shitara K, Ranceva A, Nemecek R, Santoro A, Calderon CA, Korphaisarn K, Davis T, Zahlten-Kuemeli A, Conn C, Tan M, Honeycutt H, Wainberg ZA. Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial. JCO Precis Oncol. 2025 Jan;9:e2400710. doi: 10.1200/PO-24-00710. Epub 2025 Jan 24. Erratum in: JCO Precis Oncol. 2025 Apr;9:e2500223. doi: 10.1200/PO-25-00223. PMID: 39854659; PMCID: PMC11781561.
3. Smyth EC, Kim KM, Rha SY, Wainberg ZA, Honeycutt H, Sommermann E, Ochiai A. FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma. Cancer Treat Rev. 2025 Sep;139:102971. doi: 10.1016/j.ctrv.2025.102971. Epub 2025 May 26. PMID: 40680491.

Use License Agreement

Research Use Only.

Not for use in diagnostic procedures or therapeutic applications.

Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.